Toxicological Risk Assessment Service
Device-specific TRA support for ISO 10993-17 and ISO 10993-18, built around chemical characterization, exposure logic, AET/TTC reasoning, and the reviewer-facing conclusions needed for EU MDR and FDA submissions.
AET and TTC Logic
Exposure-based toxicological reasoning tied to the actual device, contact profile, and chemistry dataset.
Chemistry Integration
TRA built around chemical characterization rather than detached from it.
Waiver Support
Useful where chemistry and toxicology are the strongest basis for avoiding unnecessary testing.
Reviewer-Facing Output
Clear conclusions that can be used in a BER, FDA summary section, or technical-file narrative.
Best for devices where chemistry is central to the biological safety argument
TRA becomes especially valuable when the device has polymers, additives, coatings, process residues, fluid pathways, prolonged contact, implant duration, or a chemistry-driven reviewer question. In those cases, the file usually needs more than a short toxicology statement. It needs a structured toxicological argument that explains why the measured or estimated exposure is or is not a real risk.
Complex Polymers or Coatings
The device includes materials, additives, coatings, lubricants, or processing aids that may drive extractables and leachables questions.
Fluid-Path or Blood Contact
The chemistry story matters because the device has prolonged fluid contact, infusion pathways, or blood-contacting surfaces.
Need Chemistry-Based Waivers
The goal is to support endpoint waivers with a stronger toxicological basis instead of defaulting to more testing.
Reviewer Raised Toxicology Questions
FDA or a notified body flagged chemistry, extractables, TTC, or overall toxicological adequacy in the submission package.
What a serious toxicological risk assessment actually covers
A strong TRA is not just a table of compounds and thresholds. It needs to show how chemistry, exposure, and toxicology fit together in a defensible safety argument.
Chemistry Dataset Review
Assessment of extractables, leachables, or chemical characterization outputs relevant to the finished device and patient-contacting state.
Exposure Assessment
Practical estimate of compound exposure under the intended use, contact duration, and device configuration that actually matters clinically.
AET and Screening Logic
Threshold-based prioritization to separate trace findings from compounds that require deeper toxicological interpretation.
Toxicological Interpretation
TTC, tolerable intake, compound-specific knowledge, and risk characterization brought together in a coherent narrative.
Link Back to the BER or Summary
The TRA conclusions are framed so they can support waived endpoints, chemistry conclusions, and the broader biological evaluation package.
Submission-Facing Conclusions
Clear statements that are usable in EU MDR, FDA, and remediation contexts instead of remaining a detached technical appendix.
Situations where TRA usually adds the most value
These are the projects where a chemistry-driven argument often improves the file more than another round of generic testing discussion.
Implants and prolonged-contact devices
Longer exposure windows often make chemistry and toxicology central to the endpoint strategy and residual-risk discussion.
Polymeric materials with additives
Plasticizers, stabilizers, antioxidants, colorants, and processing residues often need a more explicit toxicological treatment.
Coated or surface-treated devices
Coatings and treatment steps can shift the chemistry story significantly even when the base material looks familiar.
Extractables and leachables datasets
If chemistry data already exists, the submission usually needs a clear explanation of what those findings mean biologically.
Waiver-driven submission strategies
TRA often becomes the strongest scientific basis for genotoxicity, carcinogenicity, or systemic-toxicity waiver logic.
FDA or notified body chemistry questions
When reviewers ask for clarification on chemistry and toxicology, a well-structured TRA often becomes the fastest path to a defensible answer.
How a TRA scope is usually structured
The work starts with the chemistry available, the patient-contact context, and the actual regulatory question the file needs to answer.
Review Device and Chemistry Inputs
The device, contact profile, materials, manufacturing context, and available chemistry dataset are reviewed together.
Define the Exposure Logic
The relevant patient-exposure assumptions are set so the toxicological interpretation fits the device rather than a generic scenario.
Build the Toxicological Assessment
Compounds are prioritized, thresholds are applied where relevant, and the safety argument is built around traceable toxicological reasoning.
Integrate the Conclusions
The conclusions are framed so they can support the BEP, BER, FDA summary, or deficiency-response package directly.
Questions teams usually ask before scoping a TRA
Do we need chemistry data first?
Usually yes. TRA is strongest when it is built on real chemical characterization or extractables data, not on assumptions alone.
Can TRA replace all biological testing?
No. It can strengthen waived-endpoint logic and reduce unnecessary work, but it does not eliminate required evidence where testing is still needed.
Can you use an external chemistry lab dataset?
Yes. A common workflow is to interpret and integrate an existing lab output into a regulatory-grade toxicological assessment.
Is this useful for FDA and EU MDR both?
Yes. The same underlying chemistry and toxicology logic often supports both pathways, even when the reviewer-facing presentation differs.
Need a TRA that actually strengthens the submission?
Send the device type, chemistry status, pathway, and deadline. I will review the situation and tell you the likely scope, missing inputs, and next step.